Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14: 1756–1764

    CAS  Article  Google Scholar 

  2. 2

    Kantoff W et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukaemia group B 9182 study. J Clin Oncol 17: 2506–2513

    CAS  Article  Google Scholar 

  3. 3

    Berry W et al. (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443

    CAS  Article  Google Scholar 

  4. 4

    Muthuramalingam SR et al. (2004) Management of patients with hormone refractory prostate cancer. Clin Oncol 16: 505–516

    CAS  Article  Google Scholar 

  5. 5

    Oudard S et al. (2002) Preliminary results of a phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) – two schedules – versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 21: a706

    Google Scholar 

  6. 6

    Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    CAS  Article  Google Scholar 

Download references


The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information



Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Protheroe, A. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Clin Oncol 2, 68–69 (2005).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing